Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 102

Results For "2022"

1455 News Found

Zydus receives EIR from USFDA for its injectables manufacturing facility at Jarod
Biotech | May 29, 2022

Zydus receives EIR from USFDA for its injectables manufacturing facility at Jarod

The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs


Venus Remedies registers 9.22 % growth in annual sales for FY22
News | May 29, 2022

Venus Remedies registers 9.22 % growth in annual sales for FY22

The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal


USFDA approves Novartis Kymriah CAR-T cell therapy
Biotech | May 29, 2022

USFDA approves Novartis Kymriah CAR-T cell therapy

68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile


JBCL rebrands as JB
News | May 29, 2022

JBCL rebrands as JB

JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India


Torrent Pharma acquires four brands from Dr Reddy’s
News | May 27, 2022

Torrent Pharma acquires four brands from Dr Reddy’s

The integration and transition of the brands are expected to be completed by June 2022.


Bempedoic acid market in India will get crowded soon:  GlobalData
News | May 27, 2022

Bempedoic acid market in India will get crowded soon: GlobalData

Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe


New data demonstrate clinical benefit of Roche’s glofitamab
Biotech | May 27, 2022

New data demonstrate clinical benefit of Roche’s glofitamab

Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma


Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr
News | May 26, 2022

Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr

The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.


Eugia Pharma receives USFDA approval for Pemetrexed
Drug Approval | May 26, 2022

Eugia Pharma receives USFDA approval for Pemetrexed

Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)


Dr. Reddy's and Senores Pharmaceuticals launches Ketorolac Tromethamine tablets in the U.S. market
News | May 25, 2022

Dr. Reddy's and Senores Pharmaceuticals launches Ketorolac Tromethamine tablets in the U.S. market

The Toradol tablets, 10 mg brand and generic had U.S. sales of approximately US $ 16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA